Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

BACKGROUND: Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown radiosensitizing properties in preclinical studies. This open-label, single-arm trial evaluated the maximum tolerated dose (MTD; phase I) and efficacy (phase II) of vorinostat combined with standard chemoradiation in newly dia...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Galanis, Evanthia, Anderson, S Keith, Miller, C Ryan, Sarkaria, Jann N, Jaeckle, Kurt, Buckner, Jan C, Ligon, Keith L, Ballman, Karla V, Moore, Dennis F, Nebozhyn, Michael, Loboda, Andrey, Schiff, David, Ahluwalia, Manmeet Singh, Lee, Eudocia Q, Gerstner, Elizabeth R, Lesser, Glenn J, Prados, Michael, Grossman, Stuart A, Cerhan, Jane, Giannini, Caterina, Wen, Patrick Y
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2018
Ämnen:
Clinical Investigations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5909661/
https://ncbi.nlm.nih.gov/pubmed/29016887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox161
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk